CoxHealth at Home

Dermatology (drugs A-E)

(Cimzia *, Cosentyx *, Dupixent *, Enbrel *)

Patient Informati	on	Prescriber + Shipping Inform	ation	
Patient name:	DOB:	Prescriber name:		
	lale SSN:	NPI:		
Language:	Wt:□kg □lbs Ht:□cm □in	Address:		
		Apt/Suite: City:	State: Zip: _	
Apt/Suite: Cit	y: State: Zip:	Contact:		
Phone:	Alternate:	Phone:	Alternate:	
Caregiver name:	Relation:	Fax:		
	Phone:	Email:		
	Plan ID:	If shipping to prescriber: First Figure 1.	ill □ Always □ Never	
	of front and back of the insurance card(s).			
	ion (Please fax all pertinent clinical and la	·		
_	(Atopic Dermatitis)	•	, , , , , , , , , , , , , , , , , , , ,	
	(Psoriasis, unspecified) 🚨 L40.5 (Psoriati	•		
	TB test: Yes No Neg. Test Date:		s, currently treated: 🖵 Yes	□ No
	Affected areas: Palms Soles Soles			
Prior Therapy	Yes ☐ No Reason for Discontinuation of ⁻	herapy Approximate Star	t Date Approximate End	d Date
				
Comorbidities:				
Concomitant Medic	ations:			
Allergies: NKDA	Other:			
Has the patient receive	ved their starter dose(s)/kit? Yes; Start Date _	No		
Prescription		Quantity		Refill
□ Cimzia [®]	☐ Inject 400 mg SQ at weeks 0, 2 and 4	6 x 200 mg/mL	□PFS □Vials	0
(certolizumab)	☐ Inject 200 mg SQ every 2 weeks	0.000 / /	☐ PFS	
Psoriatic Arthritis	☐ Inject 400 mg SQ every 4 weeks	2 x 200 mg/mL	☐ Vials	
☐ Cosentyx [®] (secukinumab)	☐ Inject 150 mg SQ once weekly at weeks 0, 1, 2 and		☐ Sensoready [®] Pen	0
	☐ Inject 300 mg SQ once weekly at weeks 0, 1, 2 and		☐ PFS	
	☐ Inject 150 mg SQ on week 4 and every 4 weeks th☐ Inject 300 mg SQ on week 4 and every 4 weeks th		☐ Sensoready [®] Pen☐ PFS	
□ Dupixent® (dupilumab)	☐ Inject 600mg SQ on day 1, followed by 300mg SQ		PFS	0
	and every 2 weeks thereafter	-		
	☐ Inject 300mg SQ every 2 weeks	2 x 300 mg/2 mL	PFS	
□ Enbrel [®] (etanercept) Adult	☐ Inject 50 mg SQ twice a week (72-96 hours apart)	for 3 months 8 x 50 mg/mL	□ SureClick * Autoinjector □ Mini™ Cartridge	2
			PFS	
	☐ Inject 50 mg SQ every week	4 x 50 mg/mL	 SureClick[®] Autoinjector Mini[™] Cartridge 	
	<u> </u>	I	PFS	
§ Humira®, Orencia®,	Otezla® , Siliq™, Simponi®, Simponi Aria®, Stelara®, Ta	tz®, and Tremfya™ are listed alphabetical	ly on respective enrollment f	forms.§
Injection Training Pro	vided by: ☐ Physician's Office ☐ HPS	☐ Other:	ly on respective enrollment f	forms.§
Injection Training Pro		☐ Other:	ly on respective enrollment f	forms.§
Injection Training Pro	vided by: ☐ Physician's Office ☐ HPS	☐ Other:	ly on respective enrollment f	forms.§
Injection Training Pro	vided by: ☐ Physician's Office ☐ HPS	☐ Other:	ly on respective enrollment f	forms.§
Injection Training Pro Per state-specific law,	vided by: ☐ Physician's Office ☐ HPS	☐ Other:		forms.§

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure underapplicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying thisinformation. If you received this communication in error, please notify the sender immediately by calling 1 855-419-4663 to obtain instructions as to the proper destruction of the transmitted material. Thank you.

PHONE: 1-855-419-4663

FAX: 1-417-269-0692